Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556804 | 0.79 | OPRL1 (0.49) | ALDH1A1OPRL1POLBCYP2D6KMT2A | |
| SCHEMBL18304932 | 0.64 | OPRL1 (0.44) | ALDH1A1OPRL1SMN1; SMN2POLBCYP2D6 | |
| SCHEMBL19358319 | 0.64 | MEN1 (0.52) | ALDH1A1OPRL1SMN1; SMN2CYP2D6TP53 | |
| Hydrochloric Acid SCHEMBL19991781 | 0.62 | DRD2 (0.55) | ALDH1A1MAPTTSHR | |
| Hydrochloric Acid SCHEMBL18304928 | 0.62 | DRD2 (0.55) | ALDH1A1MAPTTSHR | |
| SCHEMBL18304936 | 0.62 | DRD2 (0.55) | ALDH1A1MAPTTSHR | |
| SCHEMBL1266987 | 0.61 | OPRL1 (0.58) | ALDH1A1OPRL1HSD17B10POLBCYP2D6 | |
| SCHEMBL2883677 | 0.60 | OPRL1 (0.66) | ALDH1A1OPRL1TSHRHSD17B10POLB | |
| SCHEMBL6924615 | 0.59 | OPRL1 (0.57) | ALDH1A1OPRL1TSHRSMN1; SMN2POLB | |
| SCHEMBL6967833 | 0.59 | OPRL1 (0.56) | ALDH1A1OPRL1HSD17B10POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, PDCD1 | ALDH1A1 2610/4885MAPT 996/4885OPRL1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.